Secondary Hyperparathyroidism Market Report | Secondary Hyperparathyroidism Market
Secondary hyperparathyroidism (SHPT) occurs when the parathyroid glands become enlarged and release too much PTH, causing a high blood level of PTH. Parathyroid hormone controls the level of calcium is in blood and within bones. Secondary hyperparathyroidism is commonly associated with vitamin D deficiency and chronic kidney disease (CKD). The kidney cannot convert vitamin D into the physiologically active 1,25-cholecalciferol. Reduced intestinal absorption of calcium resulting in a low serum calcium and elevated phosphate due to renal failure to excrete phosphate increases secretion of parathyroid hormone. Prolonged stimulation results in parathyroid hyperplasia. SHPT also occurs in vitamin D-deficient rickets, malabsorption, and pseudohypoparathyroidism. DelveInsight's "Secondary Hyperparathyroidism - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Secondary Hyperparathyroidism, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
78 views • 3 slides